News & Press Releases

Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.

Health Law Practice Chair and Health Care Enforcement Defense Co-chair Karen Lovitch was quoted in a recent The Dark Report article on a recent court ruling interpreting the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) and its implications for clinical labs that use independent contractors for marketing. The court decided that while paying independent sales and marketing representatives on a percentage basis is not by itself an EKRA violation, compensation arrangements could still cross the line if marketers exert “undue influence” on physicians.

Mintz advised Charlesbank Capital Partners, a middle-market private investment firm, on its acquisition of Q6 Cyber, an intelligence and fraud prevention services provider. 

Peter Saparoff, Chair of Mintz’s Institutional Investor Class Action Recovery Practice, and Associate Sofia Nuño published an article in Bloomberg Law examining how state attorneys general are increasingly applying antitrust and consumer-protection laws to asset managers’ ESG and AI stewardship practices, marking a shift toward more aggressive state-level enforcement beyond federal oversight.

Law360 featured commentary from Jason P.W. Halperin in an article about a pharmaceutical industry insider trading case brought by the DOJ. Jason and Elizabeth Platonova represented one of the defendants and negotiated a resolution in which he pled guilty and was sentenced to 15 months in prison.

Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”